vs
Insulet Corporation（PODD）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是Insulet Corporation的1.9倍（$1.5B vs $783.7M），Insulet Corporation净利率更高（13.0% vs 12.9%，领先0.1%），Insulet Corporation同比增速更快（31.2% vs 9.2%），Steris自由现金流更多（$199.5M vs $48.2M），过去两年Insulet Corporation的营收复合增速更高（33.2% vs 15.8%）
Insulet Corporation是深耕糖尿病治疗领域的医疗器械企业，核心产品为胰岛素泵，通过持续皮下输注胰岛素的疗法为患者给药。其产品通常由泵主体、一次性胰岛素储药仓，以及包含皮下植入套管和连接管路的一次性输注套件构成，满足不同患者的治疗需求。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
PODD vs STE — 直观对比
营收规模更大
STE
是对方的1.9倍
$783.7M
营收增速更快
PODD
高出22.0%
9.2%
净利率更高
PODD
高出0.1%
12.9%
自由现金流更多
STE
多$151.3M
$48.2M
两年增速更快
PODD
近两年复合增速
15.8%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $783.7M | $1.5B |
| 净利润 | $101.6M | $192.9M |
| 毛利率 | 72.6% | 43.8% |
| 营业利润率 | 18.7% | 18.3% |
| 净利率 | 13.0% | 12.9% |
| 营收同比 | 31.2% | 9.2% |
| 净利润同比 | 0.9% | 11.2% |
| 每股收益（稀释后） | $1.42 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PODDSTE
| Q4 25 | $783.7M | $1.5B | ||
| Q3 25 | $706.3M | $1.5B | ||
| Q2 25 | $649.1M | $1.4B | ||
| Q1 25 | $569.0M | $1.5B | ||
| Q4 24 | $597.5M | $1.4B | ||
| Q3 24 | $543.9M | $1.3B | ||
| Q2 24 | $488.5M | $1.3B | ||
| Q1 24 | $441.7M | $1.1B |
净利润PODDSTE
| Q4 25 | $101.6M | $192.9M | ||
| Q3 25 | $87.6M | $191.9M | ||
| Q2 25 | $22.5M | $177.4M | ||
| Q1 25 | $35.4M | $145.7M | ||
| Q4 24 | $100.7M | $173.5M | ||
| Q3 24 | $77.5M | $150.0M | ||
| Q2 24 | $188.6M | $145.4M | ||
| Q1 24 | $51.5M | $-1.4M |
毛利率PODDSTE
| Q4 25 | 72.6% | 43.8% | ||
| Q3 25 | 72.2% | 44.2% | ||
| Q2 25 | 69.7% | 45.1% | ||
| Q1 25 | 71.9% | 43.3% | ||
| Q4 24 | 72.1% | 44.5% | ||
| Q3 24 | 69.3% | 43.6% | ||
| Q2 24 | 67.7% | 44.7% | ||
| Q1 24 | 69.5% | 40.2% |
营业利润率PODDSTE
| Q4 25 | 18.7% | 18.3% | ||
| Q3 25 | 16.7% | 18.2% | ||
| Q2 25 | 18.7% | 17.7% | ||
| Q1 25 | 15.6% | 14.6% | ||
| Q4 24 | 18.3% | 17.9% | ||
| Q3 24 | 16.2% | 16.5% | ||
| Q2 24 | 11.2% | 14.5% | ||
| Q1 24 | 12.9% | 22.0% |
净利率PODDSTE
| Q4 25 | 13.0% | 12.9% | ||
| Q3 25 | 12.4% | 13.1% | ||
| Q2 25 | 3.5% | 12.8% | ||
| Q1 25 | 6.2% | 9.8% | ||
| Q4 24 | 16.9% | 12.7% | ||
| Q3 24 | 14.2% | 11.3% | ||
| Q2 24 | 38.6% | 11.4% | ||
| Q1 24 | 11.7% | -0.1% |
每股收益（稀释后）PODDSTE
| Q4 25 | $1.42 | $1.96 | ||
| Q3 25 | $1.24 | $1.94 | ||
| Q2 25 | $0.32 | $1.79 | ||
| Q1 25 | $0.50 | $1.48 | ||
| Q4 24 | $1.38 | $1.75 | ||
| Q3 24 | $1.08 | $1.51 | ||
| Q2 24 | $2.59 | $1.46 | ||
| Q1 24 | $0.73 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $423.7M |
| 总债务越低越好 | $930.8M | $1.9B |
| 股东权益账面价值 | $1.5B | $7.2B |
| 总资产 | $3.2B | $10.6B |
| 负债/权益比越低杠杆越低 | 0.61× | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资PODDSTE
| Q4 25 | — | $423.7M | ||
| Q3 25 | — | $319.2M | ||
| Q2 25 | — | $279.7M | ||
| Q1 25 | — | $171.7M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $172.2M | ||
| Q2 24 | — | $198.3M | ||
| Q1 24 | — | $207.0M |
总债务PODDSTE
| Q4 25 | $930.8M | $1.9B | ||
| Q3 25 | $934.9M | $1.9B | ||
| Q2 25 | $939.0M | $1.9B | ||
| Q1 25 | $1.6B | $1.9B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $1.4B | $2.2B | ||
| Q2 24 | $1.4B | $2.2B | ||
| Q1 24 | $1.4B | $3.1B |
股东权益PODDSTE
| Q4 25 | $1.5B | $7.2B | ||
| Q3 25 | $1.4B | $7.0B | ||
| Q2 25 | $1.5B | $7.0B | ||
| Q1 25 | $1.3B | $6.6B | ||
| Q4 24 | $1.2B | $6.4B | ||
| Q3 24 | $1.1B | $6.6B | ||
| Q2 24 | $998.4M | $6.4B | ||
| Q1 24 | $790.7M | $6.3B |
总资产PODDSTE
| Q4 25 | $3.2B | $10.6B | ||
| Q3 25 | $3.0B | $10.4B | ||
| Q2 25 | $3.5B | $10.4B | ||
| Q1 25 | $3.5B | $10.1B | ||
| Q4 24 | $3.1B | $10.0B | ||
| Q3 24 | $3.0B | $10.2B | ||
| Q2 24 | $2.9B | $10.1B | ||
| Q1 24 | $2.6B | $11.1B |
负债/权益比PODDSTE
| Q4 25 | 0.61× | 0.27× | ||
| Q3 25 | 0.68× | 0.27× | ||
| Q2 25 | 0.64× | 0.27× | ||
| Q1 25 | 1.21× | 0.29× | ||
| Q4 24 | 1.07× | 0.32× | ||
| Q3 24 | 1.21× | 0.33× | ||
| Q2 24 | 1.36× | 0.35× | ||
| Q1 24 | 1.72× | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.3M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $48.2M | $199.5M |
| 自由现金流率自由现金流/营收 | 6.2% | 13.3% |
| 资本支出强度资本支出/营收 | 17.2% | 6.6% |
| 现金转化率经营现金流/净利润 | 1.80× | 1.55× |
| 过去12个月自由现金流最近4个季度 | $377.7M | $917.1M |
8季度趋势，按日历期对齐
经营现金流PODDSTE
| Q4 25 | $183.3M | $298.2M | ||
| Q3 25 | $125.7M | $287.8M | ||
| Q2 25 | $196.5M | $420.0M | ||
| Q1 25 | $63.8M | $260.8M | ||
| Q4 24 | $147.7M | $332.8M | ||
| Q3 24 | $98.5M | $250.7M | ||
| Q2 24 | $96.5M | $303.7M | ||
| Q1 24 | $87.6M | $254.8M |
自由现金流PODDSTE
| Q4 25 | $48.2M | $199.5M | ||
| Q3 25 | $100.1M | $201.3M | ||
| Q2 25 | $177.9M | $326.4M | ||
| Q1 25 | $51.5M | $189.9M | ||
| Q4 24 | $94.1M | $243.6M | ||
| Q3 24 | $71.8M | $148.8M | ||
| Q2 24 | $74.0M | $195.7M | ||
| Q1 24 | $65.5M | $163.3M |
自由现金流率PODDSTE
| Q4 25 | 6.2% | 13.3% | ||
| Q3 25 | 14.2% | 13.8% | ||
| Q2 25 | 27.4% | 23.5% | ||
| Q1 25 | 9.1% | 12.8% | ||
| Q4 24 | 15.7% | 17.8% | ||
| Q3 24 | 13.2% | 11.2% | ||
| Q2 24 | 15.1% | 15.3% | ||
| Q1 24 | 14.8% | 14.6% |
资本支出强度PODDSTE
| Q4 25 | 17.2% | 6.6% | ||
| Q3 25 | 3.6% | 5.9% | ||
| Q2 25 | 2.9% | 6.7% | ||
| Q1 25 | 2.2% | 4.8% | ||
| Q4 24 | 9.0% | 6.5% | ||
| Q3 24 | 4.9% | 7.7% | ||
| Q2 24 | 4.6% | 8.4% | ||
| Q1 24 | 5.0% | 8.2% |
现金转化率PODDSTE
| Q4 25 | 1.80× | 1.55× | ||
| Q3 25 | 1.43× | 1.50× | ||
| Q2 25 | 8.73× | 2.37× | ||
| Q1 25 | 1.80× | 1.79× | ||
| Q4 24 | 1.47× | 1.92× | ||
| Q3 24 | 1.27× | 1.67× | ||
| Q2 24 | 0.51× | 2.09× | ||
| Q1 24 | 1.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
